01
Lao regulatory source position in the archived review
The following source entries were recorded in the earlier editorial review. Restoring that record is not a fresh verification of legal force or applicability. Confirm the current authoritative instrument and its application with the competent authority and qualified counsel.
As of 10 September 2026, the Lao PDR Trade Portal legal-document index lists an amended Law on Drugs and Medical Products and the Ministry of Health Decision on the Registration of Pharmaceutical Products No. 0622/MOH, dated 2 April 2025. These are current source records for regulatory review, not evidence that Luang Pharma or any portfolio entry has already received an authorisation.
The portal metadata for the amended law contains a date inconsistency between its displayed title and issue-date field. The official Lao text and effective provisions should therefore be checked by a qualified Lao reviewer before a filing, legal opinion or definitive compliance statement.
02
Keep the regulatory layers separate
Concerns a defined legal holder, site and authorised activity. The project location alone does not establish this status.
Concerns an identified formulation, strength, presentation, dossier, applicant/holder and jurisdiction. A generic portfolio record is not an approval.
Technical, quality, nonclinical/clinical and administrative requirements depend on product type and pathway. A dossier format is not permission to market.
The destination country determines whether registration, import permits, establishment licences or an exception are required for the specific transaction.
03
What the website does not currently claim
The website does not publish a Luang Pharma manufacturing licence number, GMP certificate, pharmaceutical-product registration number, inspection outcome, Certificate of Pharmaceutical Product, authorised distributor network or list of approved sales territories. No authentic current record supporting those statements has been supplied to this checkpoint.
The Boten facility remains described as a development-stage project. Portfolio pages are development records and must not be read as stock, approvals, prescribing information or offers to supply.
04
Regulatory evidence request
A useful diligence request identifies the company/legal-holder question, site, product reference, dosage form/presentation, target country and required evidence. Examples include a current authorisation, product-registration status, dossier component, approved label, quality document, inspection record or destination-specific eligibility document.
Document availability and disclosure are confirmed individually through professional contact. Confidential records should not be sent to the general mailbox until an appropriate transfer route is agreed.
05
Destination-country review
Registration or manufacture in one country does not automatically permit import, sale, clinical use or distribution in another. A prospective buyer, importer, distributor and marketing-authorisation holder may each have separate licensing or regulatory obligations.
Before relying on a proposed route, verify the exact product, transaction, importer role, intended use, competent authority and any applicable exemption. A free-zone or trading licence is not, by itself, medicine-market permission.
06
Regulatory source and claim control
Legal instruments, procedures and agency guidance can change. Material public claims should record the source, jurisdiction, as-of date and evidence owner; company-specific authorisation claims additionally require the authentic current document.
The regulatory and territorial notice explains the website-wide boundary. The quality page explains why product evidence and regulatory status should not be conflated.
07
Project roadmap
A manufacturing licence application follows validation, and an inspection follows the application. The roadmap below states where the project stands in that sequence.
- 01Completed
Facility design
Facility design is recorded as complete. No completion date is supplied.
- 02In progressTarget Q4 2026 · indicative
Construction and fit-out
Construction is in its final stage; completion is an indicative target.
- 03PlannedTarget Q1 2027 · indicative
Equipment installation and qualification
Installed systems would require documented qualification.
- 04PlannedTarget Q2 2027 · indicative
Process and system validation
Process and system evidence would need to be established.
- 05PlannedTarget Q3 2027 · indicative
Manufacturing licence application
Submitting an application does not establish permission to manufacture.
- 06PlannedTarget Q4 2027 · indicative
Regulatory inspection
Inspection is a separate stage from any resulting authorisation.
- 07PlannedTarget Q1 2028 · indicative
First commercial batch
Dependent on applicable permissions and demonstrated readiness.
Status reviewed . A milestone is marked completed only when the company confirms it; quarters are indicative targets. See the full project roadmap.